7 results on '"Ferrarini, Marina"'
Search Results
2. Erdheim‐Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer.
- Author
-
Cavalli, Giulio, Dagna, Lorenzo, Biavasco, Riccardo, Villa, Antonello, Doglioni, Claudio, Ferrero, Elisabetta, and Ferrarini, Marina
- Subjects
ERDHEIM-Chester disease ,MACROPHAGES ,INFLAMMATION ,CANCER ,IMMUNOSUPPRESSIVE agents ,ROAD interchanges & intersections - Abstract
Erdheim‐Chester disease (ECD) is a rare histiocytosis characterized by infiltration of multiple tissues by CD68+ foamy Mϕs (or 'histiocytes'). Clinical manifestations arise from mass‐forming lesions or from tissue and systemic inflammation. ECD histiocytes harbor oncogenic mutations along the MAPK‐kinase signaling pathway (BRAFV600E in more than half of the patients), and secrete abundant pro‐inflammatory cytokines and chemokines. Based on these features, ECD is considered an inflammatory myeloid neoplasm, and is accordingly managed with targeted kinase inhibitors or immunosuppressive and cytokine‐blocking agents. Evidence is emerging that maladaptive metabolic changes, particularly up‐regulated glycolysis, represent an additional, mutation‐driven feature of ECD histiocytes, which sustains deregulated and protracted pro‐inflammatory activation and cytokine production. Besides translational relevance to the management of ECD patients and to the development of new therapeutic approaches, recognition of ECD as a natural human model of chronic, maladaptive Mϕ activation instructs the understanding of Mϕ dysfunction in other chronic inflammatory conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis
- Author
-
Elisabetta Ferrero, Antonello Villa, Davide Stefanoni, Travis Nemkov, Angelo D’Alessandro, Isak Tengesdal, Daniela Belloni, Raffaella Molteni, Barbara Vergani, Giacomo De Luca, Greta Grassini, Maria Giulia Cangi, Lorenzo Dagna, Claudio Doglioni, Giulio Cavalli, Marina Ferrarini, Ferrero, Elisabetta, Villa, Antonello, Stefanoni, Davide, Nemkov, Travi, D'Alessandro, Angelo, Tengesdal, Isak, Belloni, Daniela, Molteni, Raffaella, Vergani, Barbara, De Luca, Giacomo, Grassini, Greta, Cangi, Maria Giulia, Dagna, Lorenzo, Doglioni, Claudio, Cavalli, Giulio, Ferrarini, Marina, Ferrero, E, Villa, A, Stefanoni, D, Nemkov, T, D'Alessandro, A, Tengesdal, I, Belloni, D, Molteni, R, Vergani, B, De Luca, G, Grassini, G, Giulia Cangi, M, Dagna, L, Doglioni, C, Cavalli, G, and Ferrarini, M
- Subjects
Proto-Oncogene Proteins p21(ras) ,Rheumatology ,3D culture, histiocytosis tissue, KRAS, immunometabolism, macrophage activation ,Macrophages ,Mutation ,MED/06 - ONCOLOGIA MEDICA ,Cytokines ,Gene Expression ,Humans ,Pharmacology (medical) ,Histiocytosis - Published
- 2021
4. A Novel Histiocytosis With Synovial and Skin Involvement
- Author
-
Elisabetta Ferrero, Giulio Cavalli, Claudio Doglioni, Lorenzo Dagna, Marina Ferrarini, Giacomo De Luca, Cavalli, Giulio, De Luca, Giacomo, Doglioni, Claudio, Ferrero, Elisabetta, Ferrarini, Marina, and Dagna, Lorenzo
- Subjects
medicine.medical_specialty ,Histiocytosis ,Text mining ,business.industry ,Internal Medicine ,medicine ,MEDLINE ,General Medicine ,business ,medicine.disease ,Dermatology - Published
- 2021
5. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease
- Author
-
Guido Pacini, Greta Pacini, Alessandro Tomelleri, Lorenzo Dagna, Giacomo De Luca, Giulio Cavalli, Marina Ferrarini, Claudio Doglioni, Pacini, Greta, Cavalli, Giulio, Tomelleri, Alessandro, De Luca, Giacomo, Pacini, Guido, Ferrarini, Marina, Doglioni, Claudio, and Dagna, Lorenzo
- Subjects
0301 basic medicine ,lcsh:Immunologic diseases. Allergy ,Chemokine ,Pathology ,medicine.medical_specialty ,genetic structures ,Immunology ,Disease ,lcsh:RC254-282 ,CCL-18 ,Pathogenesis ,03 medical and health sciences ,Disease severity ,Fibrosis ,Immunology and Allergy ,Medicine ,erdheim-chester disease ,biology ,business.industry ,Brief Report ,fibrosis ,CCL18 ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Histiocytosis ,030104 developmental biology ,Oncology ,Erdheim–Chester disease ,biology.protein ,Erdheim-Chester disease ,ccl-18 ,business ,lcsh:RC581-607 - Abstract
Erdheim-Chester disease (ECD) is a rare histiocytosis, characterized by xanthogranulomatous tissue infiltration by foamy histiocytes. Fibrosis, a histologic hallmark of ECD, is responsible for lesion growth and clinical manifestations. Unraveling molecular fibrotic pathway in ECD would allow the identification of new pharmacologic targets. In this study, we evaluated serum and tissue samples from a large cohort of ECD patients focusing on two major pro-fibrotic mediators, TGF-β1 and chemokine ligand 18 (CCL18). We found a marked increase in CCL18 but not TGF-β1 levels in serum and lesions of ECD patients (p < 0.001), independently of treatment status and consistently over time. Using a linear mathematical model, we also found that elevated CCL18 serum levels correlate with both number and severity of disease localizations. These findings suggest the involvement of CCL18-induced fibrosis in ECD pathogenesis, providing a rationale for exploring CCL18 inhibition as a treatment for progressive fibrosis in ECD.
- Published
- 2018
6. 3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target
- Author
-
Antonello Villa, Monica Rodolfo, Elisabetta Ferrero, Lorenzo Dagna, Giulio Cavalli, Marina Ferrarini, Maria Giulia Cangi, Claudio Doglioni, Daniela Belloni, Barbara Vergani, Riccardo Biavasco, Simone Cenci, Villa, Antonello, Belloni, Daniela, Vergani, Barbara, Cenci, Simone, Cavalli, Giulio, Biavasco, Riccardo, Rodolfo, Monica, Cangi, Maria Giulia, Doglioni, Claudio, Dagna, Lorenzo, Ferrero, Elisabetta, Ferrarini, Marina, Villa, A, Belloni, D, Vergani, B, Cenci, S, Cavalli, G, Biavasco, R, Rodolfo, M, Cangi, M, Doglioni, C, Dagna, L, Ferrero, E, and Ferrarini, M
- Subjects
0301 basic medicine ,Erdheim-Chester Disease ,Letter ,medicine.medical_treatment ,Immunology ,General Biochemistry, Genetics and Molecular Biology ,Proinflammatory cytokine ,Tissue Culture Techniques ,03 medical and health sciences ,0302 clinical medicine ,Bioreactors ,Rheumatology ,medicine ,Humans ,Immunology and Allergy ,Molecular Targeted Therapy ,Vemurafenib ,Protein Kinase Inhibitors ,Histiocyte ,030203 arthritis & rheumatology ,Biochemistry, Genetics and Molecular Biology (all) ,CD68 ,business.industry ,Histiocytes ,medicine.disease ,Infliximab ,Histiocytosis ,030104 developmental biology ,Cytokine ,Erdheim–Chester disease ,Cancer research ,business ,medicine.drug - Abstract
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, characterised by tissue infiltration by foamy CD68+ CD1a− histiocytes.1 The disease has pleomorphic clinical manifestations, including long bones and extraskeletal involvement, and may be life-threatening, particularly when heart and central nervous system are affected.1 ECD histiocytes secrete proinflammatory cytokines2 and carry activating mutations along the RAS-RAF-MEK-ERK protein kinase signalling pathway, most commonly the BRAFV600E oncogenic mutation.3 4 Accordingly, patients with ECD have been treated with cytokine inhibitors, including infliximab,1 ,5 and, more recently, with the BRAFV600E inhibitor vemurafenib.6 The latter, however, induces sustained but partial clinical responses and recurrences on discontinuation,6 underlining the need for more effective therapeutic strategies. To identify the outcomes downstream constitutive ERK phosphorylation in ECD histiocytes and their response to small molecule-based inhibition, we performed three-dimensional (3D) culture of tissues from three BRAFV600E-mutated ECD patients in the RCCS bioreactor7 (and online supplementary methods) in the presence/absence of vemurafenib or infliximab, used as control.### Supplementary data [annrheumdis-2018-214432supp001.pdf] All patient samples maintained production of prototypical cytokines and chemokines2 in bioreactor, thus validating this technology also for ECD; moreover, infliximab, and, to a lesser degree, vemurafenib, significantly decreased cyto-chemokines …
- Published
- 2018
7. Tocilizumab in patients with multisystem Erdheim-Chester disease
- Author
-
B. Guglielmi, Alessandro Tomelleri, Giulio Cavalli, Alvise Berti, Corrado Campochiaro, Roberto Nicoletti, Andrea Panzacchi, Riccardo Biavasco, Lorenzo Dagna, Marina Ferrarini, Berti, Alvise, Cavalli, Giulio, Guglielmi, Barbara, Biavasco, Riccardo, Campochiaro, Corrado, Tomelleri, Alessandro, Nicoletti, Roberto, Panzacchi, Andrea, Ferrarini, Marina, and Dagna, Lorenzo
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,genetic structures ,Immunology ,Erdheim–Chester disease ,Disease ,non-langerhans cell histiocytosis ,Gastroenterology ,ErdheimâChester disease ,03 medical and health sciences ,chemistry.chemical_compound ,Non-Langerhans cell histiocytosis ,tocilizumab ,0302 clinical medicine ,Tocilizumab ,non-Langerhans cell histiocytosi ,Internal medicine ,non-Langerhans cell ,medicine ,Immunology and Allergy ,Prospective cohort study ,Interleukin 6 ,RC254-282 ,medicine.diagnostic_test ,biology ,business.industry ,Brief Report ,interleukin-6 ,erdheim–chester disease ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Magnetic resonance imaging ,RC581-607 ,medicine.disease ,inflammation ,histiocytosis ,Histiocytosis ,030104 developmental biology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Immunologic diseases. Allergy ,business - Abstract
Treatment of ErdheimâChester disease (ECD), a rare non-Langerhans histiocytosis, relies on interferon-α, chemotherapeutic agents such as purine analogs, cytokine-blocking agents and BRAF inhibitors. Since interleukin (IL)-6 levels are elevated in serum and lesions of ECD patients, we evaluated the therapeutic efficacy and safety of IL-6 blockade with tocilizumab. We conducted an open-label, single-arm, phase II, prospective study of tocilizumab in three patients with multisystem ECD and poor tolerance/contraindications to IFN-α. Modifications of symptoms attributed to ECD represented the criteria for evaluation of clinical response. Changes at positron emission tomography scan, computed tomography scan, and magnetic resonance imaging at month 6 represented the main criteria for the evaluation of radiological response. Sustained complete clinical response and partial radiological improvement were observed in two patients, paralleled by modulation of systemic pro-inflammatory mediators. In spite of disease stabilization or improvement at extra-neurological sites, a third patient experienced a radiologic and clinical progression of central nervous system involvement, mirrored by a dramatic increase of circulating IL-6 and related cytokines. These findings indicate that IL-6 inhibition can be effective in ECD, but caution is advisable in patients with neurologic involvement. IL-6 emerges as a central mediator in ECD pathogenesis.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.